Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
Lessons from a former poster child
OpinionWith partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
Confo Therapeutics raise €30m in Series A financing
Latest NewsThe round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
LEA Jury announces the Winners of LEA 2019
Sponsored PublicationsResearchers report how body fat affects imune cells
Latest NewsUS scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets €36.5m support from IMI
Latest NewsThe European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
Latest NewsAlentis Therapeutics debuts with CHF12.5m
Latest NewsLiver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
Immunic appoints Tamara A. Seymour as Interim CFO
AppointmentsImmunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
EMA recommends nine drugs for market approval
Latest NewsIn its first meeting in Amsterdam, the CHMP of the European Medicines Agency recommended six new drugs, two orphan meds, and one biosimilar for EU market authorisation.
Jo Easton Appointed Non-Executive Director
AppointmentsMedica Group Plc (LSE:MGP) announces that Jo Easton has been appointed to the Group’s Board of Directors as a non-executive director. On joining the Board, Jo will be appointed to the audit, nomination and remuneration committees.